Answers are grounded in this paper and cite their sources.
Multi-center retrospective study shows HLH-like syndromes increase the risk of death and relapse in pediatric B-ALL treated with CAR T therapy, indicating critical prognosis factors.
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis-like toxicities (HLH-LT) following treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell-associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multi-center retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record. Ten percent met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (p<0.0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of non-response/relapse of 60% (95% CI [43.1-76.9]) vs. 28.2% (95% CI [20.0-36.5]), p<0.001, and non-relapse mortality of 11.4% (95% CI [0.7- 22.1]) vs. 0% (95% CI [0-0]), p<0.001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19-negative relapse of 65.2% (95% CI [44.7-85.8]) vs. 2% (95% CI [0-6.4]) in those with no HLH-like syndrome, p<0.001. Further, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19-negative relapse with a hazard ratio of 8.10 (95% CI [3.6-18.4]), p<0.001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19-negative relapse and non-relapse mortality as key outcome drivers.
No takes yet. Share an insight, caveat, or question.
McNerney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: